Giles Gwinnett is a qualified journalist and has been a reporter for a number of regional newspapers and for a press agency. He was formerly a news analyst on the German team at Thomson Financial, now Thomson Reuters. He has a bachelor’s degree in English Literature and German and a master's in Film Studies.
Last month the group revealed its Barocycler 2320EXTREME device had been selected as a finalist in the prestigious R&D 100 Awards for 2017.
Van Deventer aims to grow the firm's valuation from its current $40mln market cap to $1bn plus in the next few years
A look at what stocks are moving the needle, up and down, before the bell in New York
The firm specialises in products for ear, nose and throat and allergies ..
The Strontium Chloride 89 (SR89) injection has been approved by the FDA ..
The life sciences group is is eyeing a launch of the diagnostic test in Europe in 2018.
The firm has struck a partnership with Sphaera Pharma to develop a new analog of the drug QBM-001
The cannabis firm holds an 8% interest in both Chazz Palminteri's Bivi Vodka LLC and Christie Brinkley's Bellissima LLC.
A look at some of the analyst comment on North America listed stocks on Monday
A look at some analyst views from around the City on Friday
A look at some analyst takes on a variety of stocks on Thursday
It is doubtful of a pick-up next year though suggests Cobham as a potential recovery play if new management’s plan is appreciated by investors.